2017
DOI: 10.1093/annonc/mdx361.026
|View full text |Cite
|
Sign up to set email alerts
|

ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…The compounds have provided promising results in preclinical studies in vivo, thus, being possible future CRPC therapies. Recently, also CYP11A1 inhibitors have been developed toward reducing local androgen biosynthesis in patients with CRPC (Oksala et al 2017).…”
Section: Androgen Biosynthesis Inhibitors Serve As An Effective Appromentioning
confidence: 99%
“…The compounds have provided promising results in preclinical studies in vivo, thus, being possible future CRPC therapies. Recently, also CYP11A1 inhibitors have been developed toward reducing local androgen biosynthesis in patients with CRPC (Oksala et al 2017).…”
Section: Androgen Biosynthesis Inhibitors Serve As An Effective Appromentioning
confidence: 99%